{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:08:36Z","timestamp":1785434916674,"version":"3.56.0"},"reference-count":70,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015498","name":"Ministry for Innovation and Technology","doi-asserted-by":"publisher","award":["GINOP-2.3.2-15-2016-00043"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00043"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015498","name":"Ministry for Innovation and Technology","doi-asserted-by":"publisher","award":["TKP2021-EGA-20"],"award-info":[{"award-number":["TKP2021-EGA-20"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"award":["GINOP-2.3.2-15-2016-00043"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00043"]}],"id":[{"id":"https:\/\/ror.org\/02ey3ab96","id-type":"ROR","asserted-by":"publisher"}]},{"award":["TKP2021-EGA-20"],"award-info":[{"award-number":["TKP2021-EGA-20"]}],"id":[{"id":"https:\/\/ror.org\/02ey3ab96","id-type":"ROR","asserted-by":"publisher"}]},{"name":"European Union and the European Regional Development Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr. Issues Mol. Biol.","CIMB"],"abstract":"<jats:p>Renal cell carcinoma (RCC) is frequently resistant to tyrosine kinase inhibitors (TKIs) such as sunitinib, limiting therapeutic efficacy. ATP-binding cassette (ABC) transporters, including ABCB1, ABCB5, and ABCG2, are important transporters implicated in multidrug resistance, influencing drug efflux and tumor progression. We aimed to evaluate the expression of ABCB1, ABCB5, and ABCG2 in human RCC tissues and human renal cancer cell lines CAKI-2 and A-498, and to investigate their potential association with sunitinib resistance and associated signaling pathways. Twenty paired tumorous and adjacent non-tumorous human kidney tissue samples were analyzed for ABC transporter gene expression using qRT-PCR. RCC cell lines CAKI-2 and A-498, including sunitinib-resistant derivatives, were treated with 40 \u00b5M sunitinib. The levels of transporters and key signaling proteins were assessed by Western blot. ABCG2 was consistently higher in tumorous tissues, and ABCB1 and ABCB5 showed grade-dependent increases in tumors. Resistant cells exhibited elevated ABCB1 and dynamic ABCB5 and ABCG2 expression patterns compared to sensitive cells, indicating an association between altered transporter expression and the resistant phenotype. Sunitinib treatment modulated signaling pathways, with differential activation of PI3K\/Akt, NF-\u03baB, and MAPK\/ERK observed in sensitive versus resistant cells. Our findings suggest that altered ABCB1 and ABCG2 expression may be associated with the development of sunitinib resistance in RCC and may be linked to changes in key survival signaling pathways. These findings provide a basis for future functional studies investigating the role of ABC transporters in sunitinib resistance and may contribute to the development of personalized therapeutic strategies in RCC.<\/jats:p>","DOI":"10.3390\/cimb48070739","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:35:52Z","timestamp":1784630152000},"page":"739","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Expression of ABCB1, ABCB5, and ABCG2 Transporters in Human Renal Cell Carcinoma and Their Underlying Signaling Pathways"],"prefix":"10.3390","volume":"48","author":[{"given":"Anna","family":"Vass","sequence":"first","affiliation":[{"name":"Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary"},{"name":"Doctoral School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"Kir\u00e1ly","sequence":"additional","affiliation":[{"name":"Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erzs\u00e9bet","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary"},{"name":"HUN-REN-DE Pharmamodul Research Group, University of Debrecen, 4002 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3759-428X","authenticated-orcid":false,"given":"G\u00e1bor","family":"K\u00f3nya","sequence":"additional","affiliation":[{"name":"Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary"},{"name":"Doctoral School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Shammas","sequence":"additional","affiliation":[{"name":"Doctoral School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary"},{"name":"Department of Pharmacodynamics, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4311-9936","authenticated-orcid":false,"given":"Kriszti\u00e1n","family":"Szegedi","sequence":"additional","affiliation":[{"name":"Department of Urology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Dezs\u0151","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Juh\u00e1sz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Halmos","sequence":"additional","affiliation":[{"name":"Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsanna","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2025.06.005","article-title":"Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors","volume":"88","author":"Larcher","year":"2025","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of Renal Cell Carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","article-title":"Treatment Landscape of Renal Cell Carcinoma","volume":"24","author":"Chen","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Li, X., Xiong, W., Xiong, Z., and Zhang, X. (2025). Molecular mechanisms of renal cell carcinoma metastasis and potential targets for therapy. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1521151"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.drup.2023.100929","article-title":"Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers","volume":"67","author":"Jin","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.2008.21.7679","article-title":"Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity","volume":"27","author":"Eechoute","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Xiao, H., Zheng, Y., Ma, L., Tian, L., and Sun, Q. (2021). Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.648407"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","article-title":"Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents","volume":"142","author":"Beretta","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.20892\/j.issn.2095-3941.2019.0284","article-title":"ABC transporters and the hallmarks of cancer: Roles in cancer aggressiveness beyond multidrug resistance","volume":"17","author":"Muriithi","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2014.03.013","article-title":"Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches","volume":"347","author":"Wu","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_13","first-page":"237","article-title":"Chemotherapy-induced resistance by ATP-binding cassette transporter genes","volume":"1775","author":"Gillet","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.21873\/invivo.12877","article-title":"Expression of the Stem Cell Marker ABCB5 in Normal and Tumor Tissues","volume":"36","author":"Saeed","year":"2022","journal-title":"In Vivo"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Mignogna, C., Staibano, S., Altieri, V., De Rosa, G., Pannone, G., Santoro, A., Zamparese, R., D\u2019Armiento, M., Rocchetti, R., and Mezza, E. (2006). Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: A five year follow-up analysis. BMC Cancer, 6.","DOI":"10.1186\/1471-2407-6-293"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13046-020-1527-y","article-title":"Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma","volume":"39","author":"Lowerison","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","article-title":"Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature","volume":"54","author":"Wolking","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"101492","DOI":"10.1016\/j.jbc.2021.101492","article-title":"Dependence of ABCB1 transporter expression and function on distinct sphingolipids generated by ceramide synthases-2 and -6 in chemoresistant renal cancer","volume":"298","author":"Lee","year":"2022","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10334-005-0107-7","article-title":"Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays","volume":"18","author":"Lutz","year":"2005","journal-title":"Magma"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.trecan.2023.09.013","article-title":"Linking ABC transporters to the hallmarks of cancer","volume":"10","author":"Duvivier","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1158\/0008-5472.CAN-04-3327","article-title":"ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma","volume":"65","author":"Frank","year":"2005","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Galetti, M., Petronini, P.G., Fumarola, C., Cretella, D., La Monica, S., Bonelli, M., Cavazzoni, A., Saccani, F., Caffarra, C., and Andreoli, R. (2015). Effect of ABCG2\/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0141795"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41568-023-00612-3","article-title":"Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters","volume":"23","author":"Sajid","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Leiphrakpam, P.D., and Are, C. (2024). PI3K\/Akt\/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063178"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: New insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/dmd.118.086181","article-title":"Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function","volume":"47","author":"Robinson","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lyu, C., Wang, L., Stadlbauer, B., Buchner, A., and Pohla, H. (2022). A Pan-Cancer Landscape of ABCG2 across Human Cancers: Friend or Foe?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415955"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1158\/1078-0432.CCR-11-1667","article-title":"Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance","volume":"17","author":"Gotink","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1124\/dmd.108.024612","article-title":"Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2","volume":"37","author":"Shukla","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal Cell Carcinoma: A Review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2532954","DOI":"10.1080\/21645515.2025.2532954","article-title":"A systematic review of the latest progress of drug resistance and clinical application of immunotherapy in renal cell carcinoma in the past five years based on bibliometrics","volume":"21","author":"Wu","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Fern\u00e1ndez, L., Mill\u00e1n-Garc\u00eda, A., Merino, G., and Blanco-Paniagua, E. (2025). ABCG2 Transporter: From Structure to Function-Current Insights and Open Questions. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26136119"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Morau, M.V., Seguin, C.S., Visacri, M.B., Pincinato, E.C., and Moriel, P. (2024). Genetic Variants in the ABCB1 and ABCG2 Gene Drug Transporters Involved in Gefitinib-Associated Adverse Reaction: A Systematic Review and Meta-Analysis. Genes, 15.","DOI":"10.3390\/genes15050591"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/cpt.2833","article-title":"Association Between ABCG2, ABCB1, ABCC2 Efflux Transporter Single-Nucleotide Variants and Irinotecan Adverse Effects in Patients With Colorectal Cancer: A Real-Life Study","volume":"113","author":"Rennert","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Zuo, Y., Li, T., Yang, S., Chen, X., Tao, X., Dong, D., Liu, F., and Zhu, Y. (2024). Contribution and expression of renal drug transporters in renal cell carcinoma. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1466877"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Bielecka, Z.F., Czarnecka, A.M., and Szczylik, C. (2014). Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00194"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"106177","DOI":"10.1016\/j.ejps.2022.106177","article-title":"Role of the efflux transporters Abcb1 and Abcg2 in the brain distribution of olaparib in mice","volume":"173","author":"Song","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/15384101.2024.2306760","article-title":"Impact of sunitinib resistance on clear cell renal cell carcinoma therapeutic sensitivity in vitro","volume":"23","author":"Ghosh","year":"2024","journal-title":"Cell Cycle"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Shim, S., Nielsen, M.B., Eld, M., Stenvang, J., Br\u00f8ndum, R.F., Weber, B., Motavaf, A.K., and Ladekarl, M. (2025). ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-paclitaxel. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1558184"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"123245","DOI":"10.1016\/j.lfs.2024.123245","article-title":"The role of ABCG2 in health and disease: Linking cancer therapy resistance and other disorders","volume":"360","author":"Hamada","year":"2025","journal-title":"Life Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PGP.0b013e31829c677f","article-title":"The Multidrug-Resistance Transporter ABCB5 is Expressed in Human Placenta","volume":"33","author":"Volpicelli","year":"2014","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nbt.2284","article-title":"Combinatorial drug therapy for cancer in the post-genomic era","volume":"30","author":"Banerji","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1016\/j.bpj.2024.09.014","article-title":"Understanding the regulation of protein synthesis under stress conditions","volume":"123","author":"Irshad","year":"2024","journal-title":"Biophys. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1126\/science.278.5344.1812","article-title":"Requirement of NF-\u03baB activation to suppress p53-independent apoptosis induced by oncogenic Ras","volume":"278","author":"Mayo","year":"1997","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/ijc.26000","article-title":"Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration","volume":"130","author":"Tang","year":"2012","journal-title":"Int. J. Cancer"},{"key":"ref_47","first-page":"53","article-title":"Human ABC transporter ABCG2\/BCRP expression in chemoresistance: Basic and clinical perspectives for molecular cancer therapeutics","volume":"7","author":"Noguchi","year":"2014","journal-title":"Pharmgenomics Pers. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"101004","DOI":"10.1016\/j.drup.2023.101004","article-title":"Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer","volume":"71","author":"Bharathiraja","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Wu, C.P., Hung, C.Y., Hsieh, Y.J., Murakami, M., Huang, Y.H., Su, T.Y., Hung, T.H., Yu, J.S., Wu, Y.S., and Ambudkar, S.V. (2023). ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines. Cells, 12.","DOI":"10.3390\/cells12071056"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1080\/15548627.2015.1085742","article-title":"Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux","volume":"11","author":"Giuliano","year":"2015","journal-title":"Autophagy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2174\/138945011795378540","article-title":"Improving cancer chemotherapy with modulators of ABC drug transporters","volume":"12","author":"Shukla","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_53","first-page":"1","article-title":"Human ABCG2: Structure, function, and its role in multidrug resistance","volume":"3","author":"Mo","year":"2012","journal-title":"Int. J. Biochem Mol. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00280-013-2129-6","article-title":"Benchmarking effects of mTOR, PI3K, and dual PI3K\/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib","volume":"71","author":"Serova","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1074\/jbc.M009134200","article-title":"The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 and its catalytic activity is inhibited","volume":"276","author":"Torres","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_57","first-page":"4903","article-title":"PTEN protein phosphatase activity correlates with control of epithelial cell invasion and integrity","volume":"109","author":"Tibarewal","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/emboj.2009.395","article-title":"Coordinated regulation of p53 apoptotic targets BAX and PUMA by SMAR1 through an identical MAR element","volume":"29","author":"Sinha","year":"2010","journal-title":"EMBO J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/MCB.19.5.3485","article-title":"Transcriptional cross talk between NF-\u03baB and p53","volume":"19","author":"Webster","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-020-03524-9","article-title":"P53 vs NF-\u03baB: The role of nuclear factor-kappa B in the regulation of p53 activity and vice versa","volume":"77","author":"Lingua","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Mazumder, S., Higgins, P.J., and Samarakoon, R. (2023). Downstream Targets of VHL\/HIF-\u03b1 Signaling in Renal Clear Cell Carcinoma Progression: Mechanisms and Therapeutic Relevance. Cancers, 15.","DOI":"10.3390\/cancers15041316"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Szegedi, K., Szab\u00f3, Z., K\u00e1llai, J., Kir\u00e1ly, J., Szab\u00f3, E., Bereczky, Z., Juh\u00e1sz, \u00c9., Dezs\u0151, B., Sz\u00e1sz, C., and Zsebik, B. (2023). Potential Role of VHL, PTEN, and BAP1 Mutations in Renal Tumors. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134538"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"100905","DOI":"10.1016\/j.drup.2022.100905","article-title":"ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance","volume":"66","author":"Fan","year":"2023","journal-title":"Drug Resist. Updat."},{"key":"ref_65","first-page":"1158","article-title":"Revisiting strategies to target ABC transporter-mediated drug resistance in CNS cancer","volume":"22","author":"Amawi","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"11295","DOI":"10.18632\/oncotarget.3123","article-title":"Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation","volume":"6","author":"Brossa","year":"2015","journal-title":"Oncotarget"},{"key":"ref_67","first-page":"194","article-title":"The complexity of sunitinib dosing in renal cell cancer patients","volume":"1","author":"Desar","year":"2012","journal-title":"Transl. Androl. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1111\/bph.16252","article-title":"Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics","volume":"180","author":"Wang","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1158\/1535-7163.MCT-14-0208","article-title":"Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications","volume":"14","author":"Adelaiye","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1158\/1535-7163.MCT-11-0907","article-title":"Modulation of Akt\/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells","volume":"11","author":"Makhov","year":"2012","journal-title":"Mol. Cancer Ther."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/7\/739\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:53:32Z","timestamp":1785405212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/48\/7\/739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":70,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cimb48070739"],"URL":"https:\/\/doi.org\/10.3390\/cimb48070739","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}